Global Blood Dialyzer Market, by Product Type (Reusable and Disposable), by Dialysis Membrane Material (Cellulose Membranes and Synthetic Membranes), by End User (Hospitals, Ambulatory Surgical Centers, Home Care Settings, and Specialty Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is valued at US$ 6,241.9 million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022–2030).
Dialysis is a treatment done on patients at later stage of kidney failure (chronic renal insufficiency). This treatment is achieved by using an assembly called dialyzers, which clean blood and remove wastes and excess fluid from the body that are normally removed by healthy kidneys. In hemodialysis, blood is removed from the body and circulated through an extracorporeal fluid circuit (outside the body), then returned to the body. Hemodialyzer encloses a selectively permeable membrane acting as a filter that allows fluids and waste materials to pass through. Increasing incidence of chronic kidney diseases is expected to increase the number of dialysis process, which in turn would fuel growth of the blood dialyzers market during the forecast period. For instance, on March 18, 2022, according to the reports published by National Center for Biotechnology Information, reported that chronic kidney disease is a progressive condition that affects more than 10% of the general population worldwide, amounting to more than 800 million individuals globally. The prevalence of chronic kidney disease (CKD) varied considerably between the various laboratory-based definitions, ranging from 8327 cases per 100,000 population when using a single estimating glomerular filtration rate (eGFR) value to 4637 cases per 100,000 population when using a time-limited repeated eGFR-based (estimating glomerular filtration rate) definition globally.
Global Blood Dialyzer Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus or COVID-19 outbreak started in Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. The economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020.
The outbreak of COVID-19 has caused a significant impact on the blood dialyzer market. For instance, on August 2021, Karger, an academic publisher of scientific and medical journals and books, published a report on Impact of First Wave COVID-19 Crisis on Dialysis Parameters of COVID-Free Hemodialysis Patients: A NephoCare France Longitudinal Retrospective Cohort Study, which reported that hemodialysis (HD) delivery to COVID-free Chronic hemodialysis (HD) patients was negatively impacted in the Paris, Europe region because of the strong constraints on units’ organization related to the treatment of COVID-19+ Chronic hemodialysis (HD) patients and with a higher proportion of limited care/self-care units with less staff resources. The 3-month weight loss increase may be related to the suppression of intradialytic snack that impacted mostly the more malnourished patients or patients with lower interdialytic weight gain.
Thus, impact of the Coronavirus (COVID-19) pandemic has hindered growth of the global blood dialyzer market.
Global Blood Dialyzer Market: Key Developments
Increasing product approval by the U.S. FDA (Food and Drug Administration) to key market players in global blood dialyzer market is expected to drive growth of the global blood dialyzer market over the forecast period. For instance, on March 2021, Baxter International Inc., a multinational health care company, announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is portable and easy-to-use system to administer hemodialysis (HD) treatments. AK 98 offers encrypted and two-way connectivity, which enables the system to pull prescriptions directly from the electronic medical record (EMR) for workflow and data handling. The AK 98 system was approved to help dialysis providers minimize the operational challenges that can come with administering multiple hemodialysis sessions per machine per day.
Increasing advancement in the hemodialysis technology by key market players is expected to boost growth of the global blood dialyzer market over the forecast period. For instance, in June 2021, Baxter International Inc a multinational health care company, announced new data showing expanded hemodialysis (HDx) therapy enabled by the Theranova dialyzer (indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis) may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of Colombian dialysis patients treated with long-term hemo dialysis therapy compared to propensity-matched patients treated with High-Flux Hemodialysis.
Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on "Blood Dialyzer Market, by Product Type (Reusable, and Disposable), by Dialysis Membrane Material (Cellulose Membranes, and Synthetic Membranes), by End User (Hospitals, Ambulatory Surgical Centers, Home Care Settings, and Specialty Clinics) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2030
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/blood-dialyzer-market-2503
Rising government initiatives to advance improved treatment options for patients with kidney failure aids manufacturers to gain substantial growth in the global blood dialyzer market. For instance, in September 2018, the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) held a prize money of US $ 2,265,000 for KidneyX: Redesign Dialysis. This competition challenged manufacturers to develop better treatment options for patients with kidney failure. Thus, HHS is expecting innovations in the field of dialysis and dialyzer membranes to redesign treatment for kidney failure.
Key Takeaways of the Global Blood Dialyzer Market:
- Global blood dialyzer market is expected to exhibit a CAGR of 6.3% over the forecast period (2022–2030), owing to continuous technological advancements in dialyzers membrane
- Based on product type, disposable dialyzers are expected to receive maximum growth, owing to risks associated with reusable dialyzers.
- On the basis of dialysis membrane material, synthetic cellulose segment is expected to perceive maximum traction owing to new inorganic strategies by key market players. For instance, in November 2021, Toyobo Co., Ltd, a manufacturer and seller natural and synthetic fibers and Nipro Corporation, a medical equipment manufacturing company, decided to build new CTA (cellulose triacetate) dialyzer production plant referred as artificial kidneys. The new plant, which will be located in Nipro’s existing factory site in Odate City, Akita Prefecture, Japan, is scheduled to start operating in July 2024 to meet global demand for dialyzers which is expected to steadily increase. Such technological advancements in blood dialyzers would promote its growth in the global market during the forecast period.
- Major players involved in the global blood dialyzer market include Baxter International, Inc.,Nikkiso Co. Ltd.,B. Braun SE,CVS Health,Nipro Corporation,Diaverum Deutschland GmbH,NxStage Medical, Inc.,Fresenius Medical Care AG & Co. KGaA, DaVita Healthcare Partners, Inc.,Asahi Kasei Medical Co., Ltd,Browndove Healthcare (F) Lt.d, BAIN MEDICAL EQUIPMENT(GUANGZHOU)CO.,LTD,SB-KAWASUMI LABORATORIES, INC, Medtronic,Jihua Medical Apparatus and Instruments Co., Ltd.,Allmed Medical Care Holdings Limited. and JMS Medical Co., Ltd
